Phenylephrine Hydrochloride: Common Salt Form of the Alpha 1 Sympathomimetic
Phenylephrine hydrochloride is the common pharmaceutical salt form of the directly acting alpha 1 sympathomimetic phenylephrine. Because free phenylephrine has poor solubility in aqueous solution and is chemically less stable, the hydrochloride salt is used in virtually all medications. When you read "phenylephrine HCl" on packaging or in package inserts, this is exactly the form meant.
Clinically, phenylephrine hydrochloride is encountered in four applications: as a solution for intravenous vasopressor use in anesthesia, as eye drops for mydriasis prior to eye examinations, as a topical nasal spray for nasal congestion, and as an oral component of cold combination preparations. Pharmacologically, its properties are identical to the base; the salt form differs only in solubility, stability, and processability. A detailed pillar page on the active substance itself can be found at /wirkstoff/phenylephrin.
Mechanism of Action and Salt Form
The hydrochloride is formed by protonation of the nitrogen base in the phenylephrine molecule and binding of a chloride ion. In the body, the salt dissociates into phenylephrine and chloride within seconds, so the pharmacological effect is carried exclusively by free phenylephrine.
Phenylephrine binds selectively and with high affinity to postsynaptic alpha 1 adrenergic receptors. Via the Gq phospholipase C inositol triphosphate cascade, intracellular calcium increases and subsequently the smooth vascular muscle contracts. Clinically, vasoconstriction, increase in systemic vascular resistance, slight increase in blood pressure, and reflex bradycardia occur. On mucous membranes, phenylephrine acts locally as a decongestant.
The oral bioavailability of phenylephrine hydrochloride is only about 38 percent due to a high first pass effect. This pharmacokinetic weakness explains why oral efficacy for nasal congestion is limited in studies. In 2023, the FDA determined after evaluating new data that oral phenylephrine at approved doses is not more effective than placebo.
Indications
- Intravenous in anesthesia: Treatment of hypotension after spinal or epidural anesthesia, drug of choice for cesarean section under spinal anesthesia
- Topical nasal: Nasal drops and sprays for acute rhinitis and allergic rhinitis (short term use)
- Eye drops: Mydriasis prior to fundoscopy, cataract surgery, intraocular procedures
- Oral in cold combination preparations: Decongestant component in tablets and effervescent preparations; efficacy critically assessed
- Rarely: Intracavernosal administration for treatment of persistent priapism under medical supervision
Dosage and Administration
Intravenous: Bolus 50 to 200 micrograms, continuous infusion 25 to 100 micrograms per minute, titrated according to mean arterial pressure. Eye drops: 2.5 or 10 percent solution, one to two drops 30 to 60 minutes before the examination. In children, elderly patients, and those with cardiac disease, use the 2.5 percent solution.
Nasal: 0.25 to 0.5 percent solution, one spray per nostril every 4 hours, maximum 7 days to avoid rhinitis medicamentosa. Oral: 10 mg every 4 hours, maximum 60 mg per day in adults.
Adverse Effects
Frequent: Reflex bradycardia, blood pressure increase, headache, restlessness, sleep disturbances with oral use, local burning with nasal drops, transient vision disturbance and light sensitivity after eye drops.
Occasional to rare: Hypertensive crisis, reflex bradycardia with AV block, angina pectoris, pulmonary edema in overdose, mydriasis and acute angle closure glaucoma with eye drops, rebound nasal swelling after prolonged topical use (rhinitis medicamentosa), urinary retention in men with prostatic hyperplasia.
Important: Systemic use is contraindicated in uncontrolled hypertension, severe coronary artery disease, aortic stenosis, severe hyperthyroidism, or pheochromocytoma.
Drug Interactions
- Monoamine oxidase inhibitors (tranylcypromine, moclobemide): Hypertensive crisis, combination contraindicated
- Tricyclic antidepressants (amitriptyline): Enhanced vasoconstriction and tachycardia
- Non selective beta blockers (propranolol): Unopposed alpha effect, hypertensive reaction
- Volatile inhalational anesthetics: Increased arrhythmia risk
- Ergot alkaloids (ergotamine): Additive vasoconstriction with ischemia risk
Special Information
Pregnancy: Systemic use only after strict indication. In anesthesia for cesarean section, intravenous phenylephrine hydrochloride is considered the drug of choice for maternal hypotension under spinal anesthesia. Breast feeding: Short term applications are not considered critical.
Eye drops: The 10 percent solution can significantly increase blood pressure in infants, elderly patients, and those with cardiovascular disease, therefore prefer the 2.5 percent solution in these risk groups.
Rhinitis medicamentosa: Decongestant nasal sprays should not be used continuously for longer than 7 days, otherwise reactive mucosal swelling with chronic congestion may develop. Patients often require weeks to recover from this.
Risk of confusion in pharmacy: Phenylephrine and the formerly common phenylpropanolamine are different active substances with different profiles; phenylpropanolamine use has been discontinued in the EU due to increased stroke risk.
You May Also Be Interested In
- Phenylephrine, detailed pillar page on the active substance
- Xylometazoline, longer acting topical sympathomimetic
- Oxymetazoline, another decongestant nasal spray
- Noradrenaline, classic vasopressor in intensive care medicine
- Pseudoephedrine, orally effective alternative for nasal congestion
Frequently Asked Questions
What is the difference between phenylephrine and phenylephrine hydrochloride?
Pharmacologically none. Phenylephrine hydrochloride is only the water soluble salt form used in virtually all medications. In the body it dissociates immediately into the active phenylephrine and chloride.
Does the ingredient in cold powder really help with nasal congestion?
The US FDA committee determined in 2023 that oral phenylephrine hydrochloride at approved doses does not relieve nasal congestion better than placebo. Topical nasal spray use is not affected by this. Those seeking rapid relief benefit more from topical sprays with xylometazoline or oxymetazoline (maximum 7 days), saline rinses, or oral pseudoephedrine.
Why is the mydriasis adverse effect sometimes desired and sometimes dangerous?
In ophthalmology, pupil dilation is used to better assess the fundus. However, in patients with narrow chamber angles, mydriasis can block aqueous humor outflow and trigger an acute glaucoma attack with severe eye pain, vision disturbance, and nausea. Before eye application, the ophthalmologist asks about known narrow angle anatomy.
May I drive a car after using phenylephrine hydrochloride eye drops?
No. For several hours the pupils remain dilated, near vision is significantly blurred, and glare sensitivity is increased. Sunglasses help, but driving is still not possible. Plan for accompaniment or public transportation.
Sources
- Gelbe Liste, Phenylephrin active substance profile
- AWMF Guidelines for Anesthesia and Ophthalmology
- BfArM, Federal Institute for Drugs and Medical Devices
- EMA Summary of Product Characteristics for Phenylephrine Hydrochloride Preparations
Legal Notices and Disclaimer
The information provided on this page is for general information purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medications should only be taken as prescribed by a physician or dispensed by a pharmacy. All information is based on product information published at the time of preparation and recognized scientific sources; the currently valid product information from the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, currency, or accuracy of the information presented. In a medical emergency, call emergency number 112.